Artificial Intelligence
SciBase resolves on a fully guaranteed rights issue of approximately SEK 79.6 million
The board of directors of SciBase Holding AB (publ) (“SciBase“ or the “Company“) has today, by virtue of the authorization from the annual general meeting on 18 May 2022, resolved to carry out a fully guaranteed issue of new shares with preferential rights for existing shareholders (the “Rights Issue“) of approximately SEK 79.6 million before transaction costs.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
The board of directors of SciBase Holding AB (publ) (“SciBase“ or the “Company“) has today, by virtue of the authorization from the annual general meeting on 18 May 2022, resolved to carry out a fully guaranteed issue of new shares with preferential rights for existing shareholders (the “Rights Issue“) of approximately SEK 79.6 million before transaction costs.
Summary
- One (1) existing share in the Company entitles to nine (9) subscription rights. Twelve (12) subscription rights entitle to subscription of one (1) new share.
- The subscription price is SEK 1.55 per new share.
- The Rights Issue will provide SciBase with proceeds of approximately SEK 79.6 million before transaction costs.
- The record date for the Rights Issue will be 3 March 2023 and the subscription period will commence on 7 March 2023 and run up to and including 21 March 2023.
- The Company intends to use the net proceeds to finance reimbursement process and expansion in the U.S., and to develop new clinical applications and products within the skin barrier segment.
- The Rights Issue is comprised of approximately 52 percent subscription commitments and of approximately 48 percent issue guarantees. Accordingly, the Rights Issue is fully guaranteed.
“SciBase’s 53 percent sales growth during 2022 illustrates the exciting phase the Company is in. As well as our core business growth we see exciting growth opportunities within our new applications, as evidenced by the recent J&J partnership within skin barrier.
This Rights Issue enables us to continue expansion in our key markets Germany and especially the US, and to accelerate development of our new applications. We would like to thank both existing shareholders and new investors for their trust in our operations and continued growth journey.”
– Simon Grant, CEO, SciBase
Background and reason
SciBase is a MedTech company and a developer of AI-based solutions for skin related diseases. The Company develops products for the detection of both Melanoma and Non-melanoma skin cancer and for the evaluation of other skin diseases such as atopic dermatitis. By utilizing the products Nevisense and Nevisense Go as a platform the Company has, in addition to Melanoma, added other applications that utilize its proprietary Electrical Impedance Spectroscopy (EIS)-technology and consumable. Other applications include the detection of Non-melanoma skin cancer and the prediction and assessment of skin barrier related diseases such as atopic dermatitis.
2022 was a breakthrough year for SciBase where the Company achieved strong sales growth in key markets, made important strides in the U.S. and established the Company within the skin barrier application area. In the fourth quarter of 2022 the Company signed a strategic collaboration agreement with Johnson & Johnson Consumer Health. Sales growth is the key for SciBase and the Company has, as of today, had 10 consecutive quarters of sales growth (compared to the same periods in previous years). To continue the accelerated growth, SciBase prioritizes three key areas in line with the Company’s strategy: continued expansion in the U.S. through broader reimbursement, continued profitable sales growth in Germany, and the development of applications based on the evaluation of the skin barrier.
It is the Company’s assessment that the existing working capital is not sufficient to run the business over the next twelve months. To ensure the Company has sufficient funds for ongoing operations and development for the next twelve months the board of directors has decided to carry out the Rights Issue. The Rights Issue of approximately SEK 79.6 million, before transaction related costs, will mainly finance expansion in the U.S., and the development of new clinical applications in the category skin barrier, including development of clinical products for the applications, towards specialists and potentially towards consumers directly.
Use of issue proceeds
- Finance the Company’s strategic focus on broader public and private reimbursement in the U.S., approximately 10 percent.
- Finance continued market expansion in the U.S. and Germany, approximately 40 percent.
- Finance clinical- and product development within the skin barrier segment, approximately 20 percent.
- Finance ongoing operations, such as research, development, sales, marketing and production, approximately 30 percent.
The Rights Issue
The board of directors of SciBase has today resolved to carry out an issue of new shares with preferential rights for existing shareholders of approximately SEK 79.6 million before transaction costs. Those who are registered as shareholders on the record date, 3 March 2023, have preferential right to subscribe for new shares in the Rights Issue in relation to the number of shares held on the record date. One (1) existing share in the Company entitles to nine (9) subscription rights. Twelve (12) subscription rights entitle to subscription of one (1) new share. In addition, investors are offered the possibility to subscribe for shares without subscription rights.
If not all newly issued shares are subscribed for by exercise of subscription rights, allotment of the remaining shares shall be made within the highest amount of the Rights Issue: firstly, to those who have subscribed for shares by exercise of subscription rights (regardless of whether they were shareholders on the record date or not) and who have applied for subscription of shares without exercise of subscription rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of subscription rights that each and every one of those, who have applied for subscription of shares without exercise of subscription rights, have exercised for subscription of shares; secondly, to those who have applied for subscription of shares without exercise of subscription rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of shares the subscriber in total has applied for subscription of; and thirdly, to those who have provided issue guarantees with regard to subscription of shares, in proportion to such issue guarantees. To the extent that allotment in any section above cannot be done pro rata, allotment shall be determined by drawing of lots.
The subscription price is SEK 1.55 per new share. Provided that the Rights Issue is fully subscribed, the share capital will increase by up to SEK 2,567,816.5 by a new issue of a maximum of 51,356,330 new shares. In the event of full subscription, the Rights Issue will provide SciBase with approximately SEK 79.6 million before deduction of issue costs. Shareholders who choose not to participate in the Rights Issue will, provided that the Rights Issue is fully subscribed, have their ownership diluted by approximately 42.9 percent, but are able to financially compensate for this dilution by selling their subscription rights.
Subscription of shares shall take place during the period from and including 7 March 2023 to and including 21 March 2023. The board has the right to extend the subscription and payment period. A possible extension of the subscription period shall be announced by press release no later than the last subscription day in the Rights Issue, i.e., 21 March 2023. Trading in subscription rights takes place on Nasdaq First North Growth Market during the period from and including 7 March 2023 to and including 16 March 2023 and trading in paid subscribed shares (Sw. Betalda tecknade aktier) during the period from and including 7 March 2023 until the Rights Issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket).
Preliminary timetable
|
1 March 2023 |
Last day of trading in the SciBase share, including the right to subscribe for shares by exercising subscription rights |
|
2 March 2023 |
First day of trading in the SciBase share, excluding the right to subscribe for shares by exercising subscription rights |
|
3 March 2023 |
Record date for the right to subscribe for shares by exercising subscription rights |
|
7 March 2023 – 16 March 2023 |
Trading in subscription rights |
|
7 March 2023 – 21 March 2023 |
Subscription period |
|
23 March 2023 |
Announcement of outcome of the Rights Issue |
Complete terms and conditions and instructions for the Rights Issue as well as other information on the Company will be provided in the prospectus to be made public before the commencement of the subscription period.
Subscription commitments and issue guarantees
The Rights Issue is comprised of approximately 52 percent subscription commitments and of approximately 48 percent issue guarantees. Accordingly, the Rights Issue is fully guaranteed. Subscription commitments have been undertaken by, among others, the board members Tord Lendau, Matt Leavitt, Diana Ferro and Thomas Taapken and the management members Simon Grant, Michael Colérus, Per Svedenhag, Tobias Bergenblad, Linn Olsen and Alf Laurell as well as by the Company’s shareholder Van Herk Investments B.V., among others. Issue guarantees have been issued by external guarantors.
A guarantee commission will be paid for the issue guarantees, based on current market conditions, of eleven (11) percent of the guaranteed amount in cash consideration, or alternatively thirteen (13) percent of the guaranteed amount in the form of newly issued shares in the Company. The subscription price for any shares issued to issue guarantors shall correspond to the volume-weighted average share price (VWAP) for the Company’s share on Nasdaq First North Growth Market during the subscription period in the Rights Issue (i.e. during the period 7 March – 21 March 2023), however not lower than the subscription price per share in the Rights Issue.
No consideration is to be paid for the subscription commitments that have been entered into.
The subscription commitments and issue guarantees are not secured through bank guarantees, restricted funds, pledged assets or similar arrangements. Further information on the parties who have entered into subscription and guarantee commitments will be presented in the prospectus to be made public before the commencement of the subscription period.
Lock up undertakings
Prior to the execution of the Rights Issue, the board of directors and management of the Company have entered into lock up undertakings, which, among other things and with customary exceptions, mean that they have undertaken not to sell financial instruments in the Company held prior to the Rights Issue for a period of 180 days from announcement of outcome in the Rights Issue.
Prospectus
A prospectus and notification form will be made available before the commencement of the subscription period on SciBase’s website, http://investors.scibase.se.
Advisors
Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Rights Issue.
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “Prospectus Regulation“) and has not been approved by any regulatory authority in any jurisdiction. A prospectus will be prepared by the Company and published on the Company’s website after the prospectus has been reviewed and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act“), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
Artificial Intelligence
Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 – Exclusive Report by 360iResearch
PUNE, India, April 30, 2024 /PRNewswire/ — The report titled “Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.
“Global Expansion and Technological Advancements in Analytics Services”
Clinical trial analytics services are revolutionizing the landscape of medical research and drug development across the globe by utilizing cutting-edge data analytics and statistical methodologies to offer invaluable insights from clinical trial data. These services enhance trial efficiency, streamline costs, and boost accuracy, enabling stakeholders to refine study protocols, improve patient recruitment measures, ensure participant safety, and conduct in-depth effectiveness studies. Such analytics are pivotal in supporting clinical development strategies, facilitating smoother regulatory approvals, and aiding in ongoing market surveillance and informed decision-making. Challenges such as data privacy concerns and the substantial investments required, the sector continues to grow, driven by an increasing focus on advancing drug discoveries and the sheer volume of clinical trials. The Americas lead the market with robust clinical trial activity, supported by Europe’s push for more transparent and unified trial regulations. Meanwhile, the Middle East is emerging as a key player with significant healthcare investments, and the Asia Pacific region is recognized for its cost advantages and substantial patient demographics, becoming an attractive locale for clinical research organizations (CROs) and pharmaceutical advancements. This global momentum towards personalized medicine and heightened technology integration signifies a promising future for clinical trial analytics services in enhancing the efficacy and outcomes of clinical trials worldwide.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Revolutionizing Clinical Trials through Analytics: A New Era in Drug Discovery”
The pharmaceutical market is witnessing a significant transformation, marked by an increased focus on developing treatments for a broader spectrum of diseases, including those once deemed untreatable. This shift has propelled the expansion of clinical trials, which are now more complex due to advanced technologies, the inclusion of varied patient demographics, and stringent regulatory standards. As a result, managing and analyzing the vast amounts of data from these clinical trials has become a daunting task. Enter clinical trial analytics services, a game-changing solution that streamlines the management of these trials. These services offer indispensable insights for making strategic decisions, facilitating patient recruitment, ensuring regulatory compliance, and evaluating market potential, ultimately speeding up the delivery of new therapies. With the pharmaceutical sector’s deep investment in the quest for innovative treatments, the pivotal role of clinical trial analytics services in enhancing efficiency and driving success in drug development is clearer than ever.
“Revolutionizing Drug Development: The Power of Clinical Data Analytics”
Clinical data analytics plays a pivotal role in transforming drug development by meticulously analyzing information gathered during clinical trials. This process is key to unlocking valuable insights that lead to better clinical decisions, enhanced trial efficiency, and faster path to market for new treatments. It effectively decodes patterns, forecasts results, and elevates patient care by watching over potential adverse impacts closely. The compilation of a wide variety of data, ranging from patient demographics, clinical outcomes, to biomarkers, underpins these analytics. Innovative technologies including machine learning and artificial intelligence are at the forefront of dissecting these complex data sets to offer understandable insights. The cornerstone of this endeavor is maintaining supreme data quality, ensuring the conclusions drawn are solid and dependable. Clinical trial data management plays an instrumental role, orchestrating the collection, integration, and validation of data throughout its lifecycle. This meticulous process involves designing data capturing systems, setting standards for data collection, and closely monitoring to uphold the integrity of data. Additionally, the blueprinting and vigilant monitoring of clinical trials are critical, demanding clear goals, precise sample sizes, and thorough oversight to guarantee trial integrity and participant safety. Engaging patients in the trial process further underscores the focus on patient-centered approaches, ensuring trials are not just about data but also about the individuals who make the research possible.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“IQVIA Inc. at the Forefront of Clinical Trial Analytics Services Market with a Strong 10.57% Market Share”
The key players in the Clinical Trial Analytics Services Market include Laboratory Corporation of America Holdings, SGS S.A., QIAGEN N.V., ICON PLC, IQVIA Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trial Analytics Services Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Analytics Services Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trial Analytics Services Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Dive into the Clinical Trial Analytics Services Market Landscape: Explore 184 Pages of Insights, 574 Tables, and 26 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trial Analytics Services Market, by ServicesClinical Trial Analytics Services Market, by ComponentClinical Trial Analytics Services Market, by StagesClinical Trial Analytics Services Market, by End-UserClinical Trial Analytics Services Market, by DeploymentAmericas Clinical Trial Analytics Services MarketAsia-Pacific Clinical Trial Analytics Services MarketEurope, Middle East & Africa Clinical Trial Analytics Services MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030In Silico Clinical Trials Market – Global Forecast 2024-2030Clinical Trial Supplies Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trial-analytics-services-market-projected-to-reach-11-95-billion-by-2030—exclusive-report-by-360iresearch-302131960.html
Artificial Intelligence
Synthetik Applied Technologies LLC announces development of UrbanScale – a modeling platform for the prediction, characterization, and quantification of extreme urban heat
AUSTIN, Texas and LONDON, April 30, 2024 /PRNewswire/ — Synthetik Applied Technologies announces the development of UrbanScale, a tool to model and predict effects of extreme heat in urban areas, through a project funded by the National Oceanic and Atmospheric Association (NOAA). The physical characteristics of urban areas amplify heat effects resulting in what are known as urban heat islands — areas where surface temperatures are much higher than their surroundings. The UrbanScale tool addresses this climate peril with sophisticated analytic tools based on physics informed neural networks and cutting-edge machine learning to predict urban heat and help better understand and mitigate the risks associated with these extreme heat events. As a result of climate change, these events are expected to increase, impacting both the people that live in urban areas and the infrastructure on which they depend.
The UrbanScale platform shows significant promise to provide data on the severity of heat islands and their effects to better understand how they impact human health, energy use and damage to physical infrastructure. This information will provide a step-change in capability for government agencies, urban planners, and transportation authorities to direct efforts for mitigation and intervention. In particular, inclusion of demographic information into data pipelines will allow understanding of how urban heat effects may impact vulnerable or disadvantaged populations. Integration with climate forecasts and models will also provide unprecedented capabilities for forecasting risk associated with climate change.
Josh Hatfield, Director of Research and Development at Synthetik, said:
‘We are extremely grateful for the opportunity to study such an important issue. Extreme heat is already the largest cause of weather-related fatalities in the US, and climate change will only increase the importance of understanding heat in urban environments. Helping to meet that challenge fits directly into Synthetik’s mission.’
Synthetik COO Tim Brewer commented:
‘The UrbanScale tool will allow both our government and insurance partners to better characterize the risk of extreme heat in urban centers and promises to deliver critical insight on the way these events impact energy demands. We look forward to exploring its wide-ranging applications.’
Synthetik plans further development of UrbanScale with NOAA and other partners in the public and private sector.
For all inquiries: Contact Synthetik Applied Technologies PR [email protected]
Logo – https://mma.prnewswire.com/media/2067510/Synthetik_Applied_Technologies_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/synthetik-applied-technologies-llc-announces-development-of-urbanscale–a-modeling-platform-for-the-prediction-characterization-and-quantification-of-extreme-urban-heat-302132016.html
Artificial Intelligence
GLiNTECH – a Valiantys company, wins Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH declared Finalists for Team Excellence and ITSM Solutions
PARIS, April 30, 2024 /PRNewswire/ — Atlassian announced today that GLiNTECH – a Valiantys company has won the Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH were further declared finalists for the Team Excellence and ITSM Solutions awards, respectively.
This is an acknowledgement of their outstanding work for Atlassian customers during the calendar year 2023. This includes exceptional efforts in developing new business and driving innovative solutions for customer success.
“Our industry leading partners play a vital role in our customers’ continued success. We’re honored to highlight our top partners as award finalists this year, reflecting their ongoing commitment to delivering innovative solutions and unparalleled Atlassian services globally,” said Ko Mistry, Atlassian’s Head of Global Channels.
“We are delighted to be named as finalists for these awards from Atlassian, and we are particularly proud to celebrate GLiNTECH’s achievement in winning the Services (APAC) award.” said Emmanuel Benoit, Global Chief Executive Officer, Valiantys. “At Valiantys, embracing diversity of thought and challenging the ways our teams work has always provided Valiantys with a competitive edge to consistently deliver tangible results and value. We look to the future with unwavering determination and confidence as we continue to drive innovation and unlock potential for our customers around the globe.”
“We dedicate our IT Consulting Services and Custom Solutions to fulfilling our customers’ needs for success,” commented Dimitri Spyridopoulos, Chief Executive Officer GLiNTECH – a Valiantys company. “It’s an honor to be recognized by Atlassian as a finalist in two categories that reflect these efforts: Services and ITSM Solutions, and to be declared as winner for the Services award (APAC).”
For more information regarding this Press Release, contact: [email protected]
About Valiantys
Valiantys is a leading global consulting and services firm dedicated to Atlassian. The company accelerates business transformation by digitizing processes and modernizing teamwork, using the best agile methods and tools. Its Atlassian technical expertise is unparalleled and Valiantys supports its customers across the entire spectrum of projects on those platforms. As a recognized Agile at Scale, ITSM, and Cloud Specialized Partner, Valiantys help organizations accelerate time to value with Agile at scale, cloud, and ITSM implementations. Because teamwork requires more than just tools, the firm bridges the gap between applications and strategic practices such as SAFe® and ITIL. Over the last 15 years, Valiantys has helped more than 5,000 customers achieve their desired business outcomes at a reduced time to value, through improved team collaboration. More information about Valiantys can be found at https://www.valiantys.com/
About GLiNTECH – a Valiantys Company
GLiNTECH is a renowned Atlassian Platinum Partner headquartered in Australia and is the preferred choice for over 300 leading brands. The company has amassed more than 20 years of experience servicing enterprise clients across the Asia Pacific region, earning Atlassian Partner of the Year five times, including most recently for Professional Services. GLiNTECH is recognized as a Specialized Atlassian Cloud and ITSM partner. The company offers deep expertise in Licensing, Training, Support, Managed Services, Consulting, and Agile methodologies and has a proven record in providing reliable solutions while driving success within the Atlassian ecosystem. More information about GLiNTECH can be found here: https://www.glintech.com/
GLiNTECH was acquired by Valiantys in February 2024.
Photo – https://mma.prnewswire.com/media/2397508/GLiNTECH_2023_Services_award.jpg Logo – https://mma.prnewswire.com/media/1980997/Valiantys_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/glintech—a-valiantys-company-wins-atlassian-partner-of-the-year-2023-services-apac-award-valiantys-and-glintech-declared-finalists-for-team-excellence-and-itsm-solutions-302127386.html
-
Uncategorized6 days agoCherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence5 days agoHikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence5 days agoHITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence5 days agoWeb O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Artificial Intelligence5 days ago
Greater efforts urged on sci-tech cooperation
-
Uncategorized5 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence4 days agoCognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence5 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry
